Bengaluru-based Pandorum Technologies has raised $18 million (about ₹150 crore) in a Series B funding round, marking a significant infusion for India’s regenerative medicine sector. The round was led by Protons Corporate and included participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund and members of the Burman family.
Funds to Advance Clinical Programmes and Manufacturing
Pandorum will deploy the new capital to accelerate its clinical pipeline, strengthen regulatory capabilities and scale manufacturing infrastructure. The company said a substantial portion of the proceeds will support late-stage clinical development and the systems required for future commercialisation.
To meet global demand, Pandorum is expanding its manufacturing footprint through strategic partnerships. It has partnered with AGC Biologics in Italy to support production for the US and European markets, and with Nucelion Therapeutics — a subsidiary of Bharat Biotech — to bolster manufacturing and distribution across the Asia‑Pacific region. The company is also exploring additional collaborations in the Middle East as part of its international growth strategy.
Pipeline Focus: Disease‑Modifying Regenerative Therapies
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum combines biology, engineering and computation to develop exosome‑based regenerative therapies aimed at reprogramming diseased tissues by reducing inflammation, fibrosis and cellular dysfunction rather than merely treating symptoms.
One of the company’s lead assets, Kuragenx, is an ophthalmic therapy targeting rare ocular surface disorders such as Stevens‑Johnson Syndrome and neurotrophic keratitis. Kuragenx has received Orphan Drug Designation from the US Food and Drug Administration, a regulatory recognition that can confer incentives for developing treatments for rare diseases.
Beyond ophthalmology, Pandorum is extending its regenerative platform to explore therapeutic approaches for chronic inflammatory and degenerative conditions affecting the lungs, liver and nervous system.
Investor Confidence and Scientific Collaboration
Investors cited confidence in Pandorum’s scientific approach and long‑term potential. The financing was structured with strategic guidance from Bandana Kankani to align the company’s innovation roadmap with sustainable value creation.
Pandorum’s research and clinical activities are supported by collaborations with established clinical and academic partners, including Dr. Shroff’s Charity Eye Hospital in India, Kyoto Prefectural University of Medicine in Japan and Northwestern Medicine in the United States. These partnerships provide clinical expertise and trial sites that complement the company’s translational research capabilities.
Implications for India’s Biotech Ecosystem
The successful Series B round highlights India’s growing presence in advanced biotechnology and regenerative medicine. By combining research strength, global partnerships and scalable manufacturing, Pandorum aims to position itself as a competitive player in next‑generation therapeutics and help broaden access to regenerative treatments internationally.
